Novo Nordisk

Novo Nordisk (NVO) has escalated its feud with rival drug maker Eli Lilly (LLY) by ​seeking a ​court injunction to immediately block Lilly’s weight-loss drug ad...

Novo Nordisk (NVO) on Friday said it filed a preliminary injunction to immediately block Eli Lilly (LLY) from running obesity and diabetes drug advertisements i...

Novo Nordisk (NYSE:NVO) shares closed at US$48.18, with recent returns mixed, including a decline over the past week and gains over the past month and past 3 mo...

Key Points Novo Nordisk has sued rival GLP-1 drugmaker Eli Lilly in federal court, alleging misleading advertising. Novo alleges that Lilly's ads compare a lo...

Glp-1 Giants Take Their Battle to Court The rivalry between Novo Nordisk and Eli Lilly has escalated into a courtroom showdown, with Novo accusing its competit...

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

The lawsuit, filed in the U.S. District Court for the District of New Jersey, accuses the competitor of violating both state and federal false advertising and u...

Novo Nordisk (NVO) has filed a lawsuit against rival pharmaceutical company Eli Lilly (LLY), claiming that advertising campaigns for its weight-loss drugs are d...

Key Points Novo Nordisk is one of the leading makers of GLP-1 weight-loss drugs. The stock has a well-above-market yield that is also well above its industry...

Novo Nordisk says it sent its rival a cease-and-desist letter in April. Mads Claus Rasmussen / AFP / Getty Images Novo Nordisk NOVO.B -1.68 %decrease; down poi...